October 29, 2020
Sumitomo Dainippon Pharma enjoyed 13.4% growth in its first-half revenue thanks to the robust performance of its flagship antipsychotic Latuda (lurasidone) in North America and contributions from two Novartis diabetes drugs, which were added to its book from last November...read more